BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines amgen In-Licensed Products — Revenue Growth YoY (%) (%)
Form 10-Q / 10-K MD&A & Form 8-K Earnings Releases
Latest, Q2 2026
24.5%
Period ended Jun 30, 2026
Change on a year earlier
-15.7 pts
40.2% in Q2 2025
History
8 quarters
Since Q2 2024
Sources
8
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Amgen In-Licensed Products — Revenue Growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 24.5% | -15.7 pts | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 25.0% | -33.7 pts | Form 8-K (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 11.0% | – | Form 8-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 31.0% | -70.5 pts | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 40.2% | -41.5 pts | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 58.7% | – | Form 10-Q (filed 2025-05-07) ↗ |
| Q3 2024 | Sep 30, 2024 | 101.5% | – | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 81.7% | – | Form 10-Q (filed 2024-08-07) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Amgen In-Licensed Products — Revenue Growth YoY (%) (%), quarterly Q2 2024–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_amgen_yoy
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.